SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
TEVA Analysis & Videos »
TEVA: Bull or Bear?
Week in Preview: Election, QE2, Unemployment and More Earnings
TEVA
-24.48%
in
574 days
Filed under: Earnings Reports, Forecasts, Starbucks (SBUX), Toyota Motor Corp. (TM), Economic Data, Teva Pharm Indus ADR (TEVA), Stocks to Buy, Federal Reserve, Marathon Oil (MRO) <> It will be a busy week. Republicans are poised to gain control of the House of Representatives and gain governorships in Tuesday's mid-term elections. Also, the Federal Reserve is expected to announce another round of quantitative easing Wednesday, following the FOMC meeting. Major retailers are scheduled to report October same-store sales Thursday, while the October unemployment rate, announced on Friday, is expec...
|
Five Popular Penny Stocks to Sell Now
TEVA
+27.48%
in
677 days
Filed under: Stocks to Sell  When it comes to buying inexpensive stocks, sometimes investors think that they can find bargains for just a few dollars a share. Sometimes they are right -- but other times these penny stocks can expose your portfolio to big risk and lose you a bundle in a hurry. Here are five popular stocks under $2 a share you should avoid like the plague.
Penny stock investing tends to be riskier than investing in large cap stocks, but that doesn't mean you have to settle for losers in your quest for big penny stocks that take off. Here are five penny stock losers to avoid:<><>Cont...
|
TOPSPIN MEDICAL INC. : CHAPTER 11 BANKRUPTCY FROM ISRAEL IN DELAWARE
TEVA
|
|
|
+3.61%
in
64 days
(closed on 09/17/10)
So here it is bankruptcy from Isarael for a medical MRI (magnetic resonance imaging) technology company with only 1 employee. Read short description:
TopSpin Medical, Inc. does not have significant operations. The company focuses on raising financing to continue its operations, as well as on the examination of acquiring new business lines. Previously, it was engaged in research and development of a medical magnetic resonance imaging ( MRI ) technology using miniaturized MRI sensors. The company was founded in 1999 and is based in Givataim, Israel.
This is the case today:...
|
Five Global Favorites: 'Time to Buy'
TEVA
-29.11%
in
731 days
Filed under: International Markets, India, Newsletters, Mexico, Canada, Teva Pharm Indus ADR (TEVA), Commodities, Stocks to Buy, Israel, CEMEX S.A.B. de C.V. (CX), ICICI Bank (IBN)  "Given the stock market setback, the time to buy has come. So what is a global investor to do now? Where in the world do we go?" asks Vivian Lewis.
The editor of Global Investing reviews five global investment ideas: Mexico's Cemex (CX), Canada's Cameco (CCJ), Greece's Coca Cola Hellenic (CCH), Israel's Teva Pharmaceutcial (TEVA), and India's ICICI Bank (IBN). <>"I think this May correction has been the result of insa...
|
Abbott Deal Highlights Growth Prospects for Generic Drugs in Emerging Markets
TEVA
|
|
|
-31.02%
in
743 days
Last week, Abbott Labs (NYSE:ABT) <font> announced a collaboration </font> <font> with India-based Zydus Cadila and created a stand-alone established products division that accounts for over $5 billion in sales. ABT licensed 24 pharmaceutical products from Zydus that are focused on 15 high-growth emerging markets and the deal includes an option for over 40 additional products. Financial terms of the deal were not disclosed. </font> <> <font> The established products division consists of branded generics, which represent off-patent products subject to generic competition that are a...
|
HavRx Stock Indexes: Healthcare Continues Uptrend following Reform
TEVA
|
|
|
-11.99%
in
53 days
(closed on 05/15/10)
The healthcare sector continued its uptrend this week following the Obamacare reform plan. Many stocks in the sector are trading at multi-year or all-time highs such as hospital operator Tenet (NYSE:THC), pharmacy benefit manager (PBM) Express Scripts (NASDAQ:ESRX), and generic drug makers Mylan (NYSE:MYL) + Teva Pharma (NASDAQ:TEVA). <> <font> The continued uptrend in the healthcare sector and overall market may be more reflective of resolving the health reform issue and since many of the components of the plan do not take effect until 2014 or later; investors may also be anticipating cha...
|
Many Reasons to Launch a Global Generic Drug ETF
TEVA
|
|
|
+15.37%
in
89 days
(closed on 03/23/10)
Since I first wrote about my idea for a new generic drug exchange-traded fund ( ETF ) nearly two years ago, the global index of 80 stocks has been a strong performer as it catches up with the strong underlying fundamentals for the generic drug industry which are outlined below. 1.) approximately 70% of all prescriptions in the U.S. are filled with generic drugs; <> <> <> 2.) IMS Health estimates $135 billion in branded drug sales (including $90 billion in U.S.) will face generic competition / patent exp...
|
New Stock Indexes to Track Trends in Healthcare Sector
TEVA
|
|
|
+12.37%
in
57 days
(closed on 12/24/09)
Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. <> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index
The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
|
Teva (TEVA): Baby-boomers give boost to generics
TEVA
+14.55%
in
211 days
(closed on 05/13/10)
Filed under: International markets, Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy, Israel, Obama Picks  "The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.
In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA). <>Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic...
|
Save money, give stock to charity!
TEVA
+18.34%
in
1076 days
Filed under: Palm Inc (PALM), Teva Pharm Indus ADR (TEVA), Stocks to Sell  Surviving this recession is foremost on peoples' minds, but giving to charity is especially important in times like these. So how can you effectively give while preserving your net worth? If you plan on liquidating any profitable, or taxable, positions in the stock market thanks to the current uptrend and also want to give to your favorite charity, the strategy outlined below is key to optimizing your gift, as well as your capital. <>Though giving cash to causes is the most popular form of charity, desperate times call f...
|
Teva (TEVA): Generic profits
TEVA
+10.17%
in
140 days
(closed on 10/14/09)
Filed under: International markets, Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy, Obama Picks "Generic drug mak Teva Pharmaceutical, Ltd. (NASDAQ: TEVA) delivered respectable earnings results," says Jack Adamo, who added the stock his Insiders Plus model portfolio. "The company's earnings were up 4% on a proforma non-GAAP basis. In this case, that's the correct measurement. Net GAAP earnings were up tremendously, but aren't really representative of normal business factors. <>"Although Teva gets much of its earnings from its proprietary multiple sclerosis drug, Copaxone, its primary bu...
|
FDA, Clinical Trial Calendar Updates: THRX, GILD, TEVA, ALNY, RNUGF
TEVA
|
|
|
+10.50%
in
205 days
(closed on 10/28/09)
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description. <> The Clinical Trial Calen...
|
Momenta Pharma's Three-Part Strategy
TEVA
|
|
|
+1.69%
in
31 days
(closed on 04/06/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta...
|
People Bullish on TEVA
People Bearish on TEVA
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on TEVA |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Teva Pharmaceutical Industries Ltd
- Answers.com
"Now that health care reform has become law, what will it mean for investors in health care-related companies? One company that is likely to be among the biggest beneficiaries is Teva Pharmaceutical (
If you're looking for the most accurate way to predict the direction a stock or the market is headed, 
